Publication | Open Access
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
461
Citations
35
References
2019
Year
No survival differences were observed for patients who received bevacizumab compared with chemotherapy alone. Testing for <i>BRCA1/2</i> mutations and homologous recombination deficiency is essential.
| Year | Citations | |
|---|---|---|
Page 1
Page 1